FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2225535009> ?p ?o ?g. }

• W2225535009 endingPage "187" @default.
• W2225535009 startingPage "183" @default.
• W2225535009 abstract "Non-alcoholic fatty liver disease (NAFLD) represents one of the most common causes of chronic liver disease worldwide and is characterized by chronic liver inflammation and fibrosis leading to cirrhosis and increased risk of liver cancer in a proportion of patients. Effective anti-fibrotic agents have yet to be approved for the treatment of NAFLD. The present study aimed to evaluate the efficacy of dipeptidyl peptidase 4 inhibitors (DPP4-I) in the prevention of NAFLD progression in NAFLD patients with type 2 diabetes. The study was a single arm, multi-centre, non-randomised study of NAFLD patients with type 2 diabetes. NAFLD was diagnosed according to ultrasonographic findings. All the patients received 25 mg/day of alogliptin for 12 months. The efficacy of alogliptin in preventing NAFLD progression was assessed using overall NAFIC scores [non-alcoholic steatohepatitis (NASH), ferritin, insulin and type IV collagen 7S] and individual component scores according to baseline haemoglobin A1c (HbA1c) levels. Of the 39 patients enrolled in the study, 16 patients (40.3%) had NAFIC scores >2 points, indicating the presence of NASH. NAFIC scores markedly decreased following 12 months of alogliptin administration, but remained >2 points in 10 patients, indicating that NASH may have persisted in these patients. The relative risks for persistent NASH were 4.92 (95% confidence interval, 0.61-40.0) in the highest HbA1c tertile group compared with those in the lowest group. However, no statistically significant linear trend was observed across all HbA1c categories (P=0.145). DPP4-I may have efficacy against NAFLD progression in patients with type 2 diabetes with relatively lower HbA1c levels. DPP4-I may represent a potential new therapeutic strategy for the prevention of disease progression in NAFLD patients with type 2 diabetes." @default.
• W2225535009 created "2016-06-24" @default.
• W2225535009 creator A5000443811 @default.
• W2225535009 creator A5013005133 @default.
• W2225535009 creator A5018089559 @default.
• W2225535009 creator A5023553051 @default.
• W2225535009 creator A5026054845 @default.
• W2225535009 creator A5028037103 @default.
• W2225535009 creator A5029872504 @default.
• W2225535009 creator A5036475624 @default.
• W2225535009 creator A5038609824 @default.
• W2225535009 creator A5039741962 @default.
• W2225535009 creator A5039953961 @default.
• W2225535009 creator A5043922565 @default.
• W2225535009 creator A5050842254 @default.
• W2225535009 creator A5053080474 @default.
• W2225535009 creator A5055409975 @default.
• W2225535009 creator A5064599050 @default.
• W2225535009 creator A5068495547 @default.
• W2225535009 creator A5075622734 @default.
• W2225535009 creator A5075687862 @default.
• W2225535009 creator A5088063298 @default.
• W2225535009 creator A5088201629 @default.
• W2225535009 date "2016-01-07" @default.
• W2225535009 modified "2023-10-16" @default.
• W2225535009 title "Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes" @default.
• W2225535009 cites W1622799587 @default.
• W2225535009 cites W1975016799 @default.
• W2225535009 cites W1977533715 @default.
• W2225535009 cites W1981294971 @default.
• W2225535009 cites W2000641576 @default.
• W2225535009 cites W2010450923 @default.
• W2225535009 cites W2026049223 @default.
• W2225535009 cites W2040109162 @default.
• W2225535009 cites W2051987387 @default.
• W2225535009 cites W2055183906 @default.
• W2225535009 cites W2076733640 @default.
• W2225535009 cites W2078391360 @default.
• W2225535009 cites W2079072815 @default.
• W2225535009 cites W2097395605 @default.
• W2225535009 cites W2108940430 @default.
• W2225535009 cites W2115395171 @default.
• W2225535009 cites W2158129157 @default.
• W2225535009 cites W2341236811 @default.
• W2225535009 cites W2469296792 @default.
• W2225535009 cites W44144113 @default.
• W2225535009 doi "https://doi.org/10.3892/br.2016.569" @default.
• W2225535009 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4734121" @default.
• W2225535009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26893835" @default.
• W2225535009 hasPublicationYear "2016" @default.
• W2225535009 type Work @default.
• W2225535009 sameAs 2225535009 @default.
• W2225535009 citedByCount "39" @default.
• W2225535009 countsByYear W22255350092016 @default.
• W2225535009 countsByYear W22255350092017 @default.
• W2225535009 countsByYear W22255350092018 @default.
• W2225535009 countsByYear W22255350092019 @default.
• W2225535009 countsByYear W22255350092020 @default.
• W2225535009 countsByYear W22255350092021 @default.
• W2225535009 countsByYear W22255350092022 @default.
• W2225535009 crossrefType "journal-article" @default.
• W2225535009 hasAuthorship W2225535009A5000443811 @default.
• W2225535009 hasAuthorship W2225535009A5013005133 @default.
• W2225535009 hasAuthorship W2225535009A5018089559 @default.
• W2225535009 hasAuthorship W2225535009A5023553051 @default.
• W2225535009 hasAuthorship W2225535009A5026054845 @default.
• W2225535009 hasAuthorship W2225535009A5028037103 @default.
• W2225535009 hasAuthorship W2225535009A5029872504 @default.
• W2225535009 hasAuthorship W2225535009A5036475624 @default.
• W2225535009 hasAuthorship W2225535009A5038609824 @default.
• W2225535009 hasAuthorship W2225535009A5039741962 @default.
• W2225535009 hasAuthorship W2225535009A5039953961 @default.
• W2225535009 hasAuthorship W2225535009A5043922565 @default.
• W2225535009 hasAuthorship W2225535009A5050842254 @default.
• W2225535009 hasAuthorship W2225535009A5053080474 @default.
• W2225535009 hasAuthorship W2225535009A5055409975 @default.
• W2225535009 hasAuthorship W2225535009A5064599050 @default.
• W2225535009 hasAuthorship W2225535009A5068495547 @default.
• W2225535009 hasAuthorship W2225535009A5075622734 @default.
• W2225535009 hasAuthorship W2225535009A5075687862 @default.
• W2225535009 hasAuthorship W2225535009A5088063298 @default.
• W2225535009 hasAuthorship W2225535009A5088201629 @default.
• W2225535009 hasBestOaLocation W22255350091 @default.
• W2225535009 hasConcept C126322002 @default.
• W2225535009 hasConcept C134018914 @default.
• W2225535009 hasConcept C156490143 @default.
• W2225535009 hasConcept C2777180221 @default.
• W2225535009 hasConcept C2777214474 @default.
• W2225535009 hasConcept C2778772119 @default.
• W2225535009 hasConcept C2779102576 @default.
• W2225535009 hasConcept C2779134260 @default.
• W2225535009 hasConcept C2779478299 @default.
• W2225535009 hasConcept C2780012697 @default.
• W2225535009 hasConcept C2780559512 @default.
• W2225535009 hasConcept C555293320 @default.
• W2225535009 hasConcept C71924100 @default.
• W2225535009 hasConcept C90924648 @default.
• W2225535009 hasConceptScore W2225535009C126322002 @default.

• next